PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
15
5
2020
Statut:
ppublish
Résumé
Optimal adherence to oral pre-exposure prophylaxis (PrEP) for HIV prevention involves aligning consistent PrEP use with periods of risk to achieve prevention-effective adherence. Prevention-effective adherence is predicated on individuals discontinuing PrEP during periods without expected risk. For stable, serodiscordant couples, antiretroviral therapy (ART) adherence by the HIV-positive partner markedly decreases HIV transmission risk, potentially obviating the need for continued PrEP use; yet little is known about actual lived experiences of discontinuing PrEP. In-depth qualitative interviews were conducted with HIV-uninfected PrEP users in serodiscordant couples taking part in the Partners Demonstration Project at IDI-Kasangati, Kampala, Uganda. Open-ended interviews elicited information on the partnered relationship; understandings of PrEP; prevention strategies; and experiences of PrEP discontinuation. An inductive, thematic, content-analytic approach was used to analyze study data. Uninfected partners experienced PrEP as a valued resource for preventing HIV acquisition. Despite ongoing ART use by HIV-positive partners for a period of time consistent with viral suppression, discontinuation of PrEP was experienced as a loss of protection and a corresponding increase in risk of HIV acquisition. Uninfected partners responded with strategies aimed at offsetting this subjective sense of increased risk, specifically: (1) changing sexual practices; (2) prioritizing fidelity in the relationship; (3) increasing reliance on condoms; and (4) seeking evidence of partners' ART adherence. These experiences highlight the challenges PrEP users in serodiscordant couples face in discontinuing PrEP for prevention-effective adherence. Flexible interventions that support individuals during this transition may increase comfort with discontinuing PrEP when alternative prevention strategies provide protection, such as a partner's consistent adherence to ART.
Sections du résumé
BACKGROUND
Optimal adherence to oral pre-exposure prophylaxis (PrEP) for HIV prevention involves aligning consistent PrEP use with periods of risk to achieve prevention-effective adherence. Prevention-effective adherence is predicated on individuals discontinuing PrEP during periods without expected risk. For stable, serodiscordant couples, antiretroviral therapy (ART) adherence by the HIV-positive partner markedly decreases HIV transmission risk, potentially obviating the need for continued PrEP use; yet little is known about actual lived experiences of discontinuing PrEP.
METHODS
In-depth qualitative interviews were conducted with HIV-uninfected PrEP users in serodiscordant couples taking part in the Partners Demonstration Project at IDI-Kasangati, Kampala, Uganda. Open-ended interviews elicited information on the partnered relationship; understandings of PrEP; prevention strategies; and experiences of PrEP discontinuation. An inductive, thematic, content-analytic approach was used to analyze study data.
RESULTS
Uninfected partners experienced PrEP as a valued resource for preventing HIV acquisition. Despite ongoing ART use by HIV-positive partners for a period of time consistent with viral suppression, discontinuation of PrEP was experienced as a loss of protection and a corresponding increase in risk of HIV acquisition. Uninfected partners responded with strategies aimed at offsetting this subjective sense of increased risk, specifically: (1) changing sexual practices; (2) prioritizing fidelity in the relationship; (3) increasing reliance on condoms; and (4) seeking evidence of partners' ART adherence.
CONCLUSIONS
These experiences highlight the challenges PrEP users in serodiscordant couples face in discontinuing PrEP for prevention-effective adherence. Flexible interventions that support individuals during this transition may increase comfort with discontinuing PrEP when alternative prevention strategies provide protection, such as a partner's consistent adherence to ART.
Identifiants
pubmed: 31609925
doi: 10.1097/QAI.0000000000002139
pii: 00126334-201911010-00006
pmc: PMC6812551
mid: NIHMS1534875
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-274Subventions
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH095507
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH098744
Pays : United States
Références
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Lancet HIV. 2017 Nov;4(11):e475
pubmed: 29096785
PLoS One. 2014 Feb 21;9(2):e89118
pubmed: 24586534
AIDS Behav. 2015 May;19(5):784-93
pubmed: 25416076
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8
pubmed: 24784763
J Int AIDS Soc. 2018 May;21(5):e25113
pubmed: 29851436
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
J Int AIDS Soc. 2016 Feb 04;19(1):20642
pubmed: 26850270
AIDS Behav. 2016 Jul;20(7):1400-7
pubmed: 26538056
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Gates Open Res. 2018 Jan 30;1:3
pubmed: 29355231
Cult Health Sex. 2017 Dec;19(12):1301-1313
pubmed: 28415911
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):206-12
pubmed: 24828268
Cult Health Sex. 2016 Sep;18(9):1081-91
pubmed: 27093238
AIDS Behav. 2011 Jul;15(5):959-69
pubmed: 20844946
J Int AIDS Soc. 2019 Jan;22(1):e25225
pubmed: 30657642
AIDS Behav. 2013 Oct;17(8):2732-41
pubmed: 23420102
AIDS Behav. 2018 Nov;22(11):3468-3479
pubmed: 29404757
Soc Sci Med. 2006 Mar;62(6):1369-80
pubmed: 16146666
Curr Opin HIV AIDS. 2016 Jan;11(1):10-7
pubmed: 26633638
J Int AIDS Soc. 2016 Dec 12;19(1):21134
pubmed: 27964776
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
AIDS Care. 2008 Jul;20(6):733-40
pubmed: 18576176
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):555-63
pubmed: 25393942
PLoS Med. 2016 Aug 23;13(8):e1002099
pubmed: 27552090
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Int AIDS Soc. 2017 Jul 25;20(1):21842
pubmed: 28741331
AIDS Behav. 2010 Dec;14(Suppl 2):189-203
pubmed: 20838872
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):463-8
pubmed: 22267018
Am J Public Health. 2002 Mar;92(3):378-81
pubmed: 11867314
AIDS Care. 2016 Aug;28(8):1000-6
pubmed: 26754017
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095
Violence Against Women. 2009 Dec;15(12):1509-25
pubmed: 19850959
J Acquir Immune Defic Syndr. 2017 Jan 1;74 Suppl 1:S15-S22
pubmed: 27930607